| Theresa E Hammerquist, MSN, APRN, NP-C, CNP | |
|
109 Pugh St, Martin, SD 57551-7700 | |
| (605) 685-6868 | |
| Not Available |
| Full Name | Theresa E Hammerquist |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Primary Care |
| Location | 109 Pugh St, Martin, South Dakota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982194049 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP2300X | Nurse Practitioner - Primary Care | CP001376 (South Dakota) | Primary |
| Entity Name | Avera Mckennan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003389206 PECOS PAC ID: 0345157103 Enrollment ID: O20031110000117 |
News Archive
Generex Biotechnology Corporation today announced its receipt of a decision by the NASDAQ Listing Qualifications Panel, which granted the Company's request for continued listing of the Company's common stock on The NASDAQ Stock Market on an interim basis, subject to certain conditions subsequent which are described in the Form 8-K Current Report filed by the Company with the Securities and Exchange Commission on EDGAR earlier today.
Poor-quality sleep marked by frequent awakenings can speed cancer growth, increase tumor aggressiveness and dampen the immune system's ability to control or eradicate early cancers, according to a new study published online January 21, 2014, in the journal Cancer Research.
BioControl Medical has announced U.S. Food and Drug Administration approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company's CardioFit system for heart failure.
Results from the safety trial - on patients with blood cancer - found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition.
When is it appropriate to treat short children with growth hormone? The answer is not always clear-cut, as many parents and physicians have discovered over the past three decades.
› Verified 2 days ago
| Entity Name | Horizon Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356459382 PECOS PAC ID: 8921997933 Enrollment ID: O20040315000974 |
News Archive
Generex Biotechnology Corporation today announced its receipt of a decision by the NASDAQ Listing Qualifications Panel, which granted the Company's request for continued listing of the Company's common stock on The NASDAQ Stock Market on an interim basis, subject to certain conditions subsequent which are described in the Form 8-K Current Report filed by the Company with the Securities and Exchange Commission on EDGAR earlier today.
Poor-quality sleep marked by frequent awakenings can speed cancer growth, increase tumor aggressiveness and dampen the immune system's ability to control or eradicate early cancers, according to a new study published online January 21, 2014, in the journal Cancer Research.
BioControl Medical has announced U.S. Food and Drug Administration approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company's CardioFit system for heart failure.
Results from the safety trial - on patients with blood cancer - found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition.
When is it appropriate to treat short children with growth hormone? The answer is not always clear-cut, as many parents and physicians have discovered over the past three decades.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Theresa E Hammerquist, MSN, APRN, NP-C, CNP 11515 Nemo Rd, Rapid City, SD 57702-6182 Ph: (605) 430-0304 | Theresa E Hammerquist, MSN, APRN, NP-C, CNP 109 Pugh St, Martin, SD 57551-7700 Ph: (605) 685-6868 |
News Archive
Generex Biotechnology Corporation today announced its receipt of a decision by the NASDAQ Listing Qualifications Panel, which granted the Company's request for continued listing of the Company's common stock on The NASDAQ Stock Market on an interim basis, subject to certain conditions subsequent which are described in the Form 8-K Current Report filed by the Company with the Securities and Exchange Commission on EDGAR earlier today.
Poor-quality sleep marked by frequent awakenings can speed cancer growth, increase tumor aggressiveness and dampen the immune system's ability to control or eradicate early cancers, according to a new study published online January 21, 2014, in the journal Cancer Research.
BioControl Medical has announced U.S. Food and Drug Administration approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company's CardioFit system for heart failure.
Results from the safety trial - on patients with blood cancer - found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition.
When is it appropriate to treat short children with growth hormone? The answer is not always clear-cut, as many parents and physicians have discovered over the past three decades.
› Verified 2 days ago
Ms. Cynthia Elaine Boltz, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 109 Pugh St, Martin, SD 57551 Phone: 605-685-6868 Fax: 866-423-6811 | |
Jennifer Risse, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 102 Major Allen St, Martin, SD 57551 Phone: 605-685-1660 Fax: 605-685-1166 |